Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
3.240
+0.060 (1.89%)
Mar 20, 2026, 4:00 PM EDT - Market closed
Cellectar Biosciences Employees
Cellectar Biosciences had 11 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
11
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,981,003
Market Cap
13.74M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 11 | 0 | - |
| Dec 31, 2024 | 11 | -9 | -45.00% |
| Dec 31, 2023 | 20 | 5 | 33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IO Biotech | 78 |
| BioCardia | 20 |
| Soligenix | 16 |
| Phio Pharmaceuticals | 6 |
| Quoin Pharmaceuticals | 5 |
| Cadrenal Therapeutics | 4 |
| Jupiter Neurosciences | 4 |
| Hoth Therapeutics | 3 |
CLRB News
- 16 days ago - Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - GlobeNewsWire
- 23 days ago - Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 - GlobeNewsWire
- 4 weeks ago - Cellectar Biosciences Expands Global Intellectual Property Estate - GlobeNewsWire
- 2 months ago - Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies - GlobeNewsWire
- 4 months ago - Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research - GlobeNewsWire
- 6 months ago - Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 - GlobeNewsWire